Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
“Another top-five holding is Lifecore (LFCR). The entire thesis is that they can sell their excess manufacturing capacity. The company has announced seven new customers in the past nine months, and while the customers are not named specifically, breadcrumbs indicate at least two large customers. Public investors do not appear to fully value Lifecore's contract wins because lengthy FDA approval processes delay the associated revenue. Yet those approvals also make the contracts exceptionally sticky, a characteristic private investors are typically more willing to value. I continue to believe the shares will trade higher or the company will be sold. A recent SEC filing indicated that the company continues to evaluate a range of strategic alternatives. Insiders own more than 30% of the company, and in most scenarios I model, a sale would occur at a substantial premium to today's share price, potentially more than 100%.” | BULL | Q2 2026 Aug 14, 2026 | View Pitch | |
Laughing Water Capital Matthew Sweeney | “Take for example our investment in Lifecore Biomedical, our CDMO that puts injectable drugs into syringes and vials. I have written about this investment extensively in the past, but in brief, Lifecore has excess capacity in a market where there is a global shortage of capacity, demand is growing, and new supply cannot be quickly or effectively built because of a limited supply chain and regulatory barriers. Additionally, customers shop on quality control above all else, and new facilities cannot demonstrate a long track record of effective quality control. It is nearly impossible to imagine scenarios where Lifecore does not fill their existing capacity absent completely destroying their ~40 year record of quality control, and incremental business is very sticky and comes with high margins. A new management team has been racking up customer wins and taking out costs. Private market value multiples suggest considerable upside for the stock, and a past sale process received low ball bids near the current stock price, suggesting downside protection is real. BSD Analysis: Lifecore is a contract manufacturer exposed to biotech funding cycles. The moat is technical capability and regulatory qualification, but customer concentration matters. Margins depend on utilization and mix. Execution issues show up quickly in cash flow. The failure mode is underutilized capacity plus leverage. The bull case is stabilized biotech demand and operational cleanup. Lifecore is a turnaround execution story. Balance sheet discipline decides survival.” | BULL | Q4 2025 Jan 1, 2026 | View Pitch |
Laughing Water Capital Matthew Sweeney | “Lifecore Biomedical Inc. (LFCR) – Lifecore, our fill-finish CDMO, continues to work toward their dual goals of increasing capacity utilization and expanding margins. I continue to believe that achieving these goals is very much a “when” rather than an “if.” This belief was founded on global supply and demand dynamics, strengthened by the BIOSECURE Act, and reinforced by the National Security Commission delivering a report and action plan to Congress, which calls for the re-shoring of the biotech supply chain. To top it off, Trump has recently stated that pharmaceuticals manufactured abroad will be subject to 200% tariffs. Considering that building and certifying new fill-finish capacity can take 4 or 5 years, it seems that it would be much easier to partner with a company like Lifecore. The sales cycle here is slow, but all indications are that the pipeline is active, and major international pharma and biotech companies have been conducting diligence on Lifecore's facilities. Shares continue to trade well below where frequent industry M&A has taken place, and as the last public domestic CDMO of any size, I believe LFCR will eventually be acquired. ~6x revenue would be a reasonable multiple based on past transactions, suggesting a price of more than $13 per share today, and closer to $16 on 2026 numbers. BSD Analysis: Lifecore is trying to go from “interesting CDMO niche” to “go-to partner for complex injectables,” and the recent big-pharma manufacturing wins suggest that pivot is working. The company's hyaluronic-acid history gives it deep formulation expertise that it can parlay into broader sterile-injectable work. Fill-finish capacity remains scarce industry-wide, which puts decent pricing power in Lifecore's hands if it executes flawlessly. The wild card is always capital structure and governance, both of which have been messy enough to scare off more conservative investors. That overhang is also where the opportunity lives—if the operations keep delivering, the financials can be cleaned up later. This is not the safest CDMO to own, but it might be one of the more mispriced if the current contracts ramp the way management suggests.” | BULL | Q2 2025 Jul 1, 2025 | View Pitch |
“LifeCore is a contract drug manufacturer which has recently added significant manufacturing capacity. They are operating at approximately 20% of their capacity with 15% EBITDA margins. Trump has repeated a desire to impose a 200% tariff on drugs made outside of the US. While our investment thesis is not based on the imposition of additional tariffs, if imposed, it would be a gift to the business development team at LifeCore, which has a ton of capacity to sell. At the company's investor day in 2024, LifeCore management provided medium and long-term guidance indicating they could nearly quadruple EBITDA with no additional capital. Management may have been conservative given potentially higher pricing, and tariff-driven reshoring could magnify demand. The multiyear path to a multibagger remains intact. BSD Analysis: LifeCore has significant unutilized capacity, which drives enormous operating leverage once drug fills accelerate. Tariff-driven reshoring would amplify already-strong secular demand for U.S.-based sterile manufacturing. EBITDA expansion potential is substantial given low current utilization, with fixed-cost absorption driving margin uplift. Execution risk remains around customer onboarding, FDA approvals, and pricing assumptions, but risk/reward is attractive.” | BULL | Q2 2025 Jul 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
